Download video

DESTINY-Breast03: T-DXd nel tumore della mammella metastatico HER2+

243 views

OncoInfoTV

6 months ago

DESTINY-Breast03: T-DXd nel tumore della mammella metastatico HER2+

DESTINY-Breast03: T-DXd nel tumore della mammella metastatico HER2+

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer
1:08
Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer
by VJOncology
DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer
2:48
DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer
by VJOncology
Highlights from ESMO: DESTINY-Breast03
0:48
Highlights from ESMO: DESTINY-Breast03
by VJOncology
SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03
2:16
SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03
by VJOncology
Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer
1:20
Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer
by VJOncology
DESTINY-Breast03: practice-changing results from ESMO 2021
2:27
DESTINY-Breast03: practice-changing results from ESMO 2021
by VJOncology
DESTINY-Breast03: T-DXd nel tumore della mammella metastatico HER2+
4:52
DESTINY-Breast03: T-DXd nel tumore della mammella metastatico HER2+
by OncoInfoTV
DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1
1:08
DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1
by VJOncology
Choosing between tucatinib and T-DXd in HER2+ breast cancer
1:46
Choosing between tucatinib and T-DXd in HER2+ breast cancer
by VJOncology
DESTINY-Breast03: safety follow-up results
4:25
DESTINY-Breast03: safety follow-up results
by VJOncology
Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer
2:02
Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer
by OncLive
DESTINY-Breast04: T-DXd for patients with HER2-low mBC
0:56
DESTINY-Breast04: T-DXd for patients with HER2-low mBC
by VJOncology
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and\/or mBC previo...
7:12
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and\/or mBC previo...
by ecancer
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
2:31
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
by VJOncology
#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer
7:30
#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer
by European Society for Medical Oncology (ESMO)
TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis
0:53
TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis
by VJOncology
DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer
3:09
DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer
by VJOncology
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients
5:57
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients
by ecancer
DESTINY-Breast12: T-DXd in patients with HER2+\/HR- breast cancer with brain metastasis
0:44
DESTINY-Breast12: T-DXd in patients with HER2+\/HR- breast cancer with brain metastasis
by VJOncology
DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvement
4:15
DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvement
by VJOncology